|Company:||CytImmune Sciences Inc||Website:||www.cytimmune.com/|
|Contact:||Lawrence Tamarkin (CEO)||Phone:||(240) 864-2791|
|E-mail:||N/A||Address:||9640 Medical Center Drive Rockville, MD 20850|
|Category:||Nanomedicine||Public Company:||Nasdaq: LIFE|
CytImmune Sciences is developing targeted chemotherapy medicines which utilizes colloidal gold nanoparticles to deliver drugs directly to cancer tumors.
CytImmune uses a combination of techniques to target the nanoparticle to cancer tumors. First, the nanoparticle is designed to be too big to exit most healthy blood vessels, however some blood vessels located at the site of tumors are leaky, allowing the nanoparticle to exit the blood vessel at the tumor site. They also attach molecules of a tumor-killing agent called tumor necrosis factor alpha (TNF) to the nanoparticle, as well as molecules of Thiol-derivatized polyethylene glycol (PEG-THIOL). PEG-THIOL hides the TNF bearing nanoparticle from the immune system allowing the nanoparticle to flow through the blood stream without being attacked. Once the nanoparticle is in the region of a cancer tumor TNF molecules bind the nanoparticle to cancer cells.
Nanomedicine Related Products
Aurmine(CYT6091): Gold nanoparticle with molecules of TNF attached as well as molecules of PEG-THIOL. Preliminary results of a phase 1 clinical trial have been published. CytImmune is planning a phase 2 trial with Aurmine combined with other chemotherapy drugs, such combinations are known to increase the effectiveness of chemotherapy, the plan here is to have the benefits brought from such a combination while minimizing the negative effects of TNF on non cancer cells.
AuriTol(CYT21001): Gold nanoparticle with molecules of TNF and PEG-THIOL attached as well as molecules of a chemotherapy drug called paclitaxel bound to the surface of the nanoparticle. AuriTol is currently in pre-clinical trial. You can see some details of about AuriTol on this slide.
Product Development Affiliations
CytrImmune has an agreement with the University of Maryland Biotechnology Institute (UMBI)that will allow the manufacture of CytImmune's AuriTol targeted chemotherapy drug , to be used for clinical testing, in UMBI's Biomanufacturing Facility.
Subsidiaries or Parent Company
Primary Investors or Funding Source